|1.||Thompson, W Joseph: 12 articles (07/2008 - 03/2002)|
|2.||Weinstein, I Bernard: 10 articles (07/2008 - 04/2002)|
|3.||Pamukcu, Rifat: 9 articles (10/2003 - 02/2002)|
|4.||Pamukcu, R: 6 articles (11/2001 - 07/2000)|
|5.||Bunn, Paul A: 5 articles (10/2007 - 02/2002)|
|6.||Deguchi, Atsuko: 5 articles (01/2006 - 08/2002)|
|7.||Piazza, Gary: 5 articles (05/2004 - 02/2002)|
|8.||Thompson, W J: 5 articles (11/2001 - 07/2000)|
|9.||Li, Han: 4 articles (07/2008 - 08/2002)|
|10.||Xiao, Danhua: 4 articles (01/2006 - 04/2002)|
08/01/2006 - "Sulindac sulfone is one of the new therapeutic apoptotic agents that show promise in the treatment of cancer. "
09/01/2012 - "These data suggest that NO-exisulind reduces tumor growth and inhibits tumor progression by blocking proliferation, inducing apoptosis and reducing EMT."
09/01/2012 - "We found that the topical treatment with NO-exisulind significantly reduced UVB-induced tumors in SKH-1 hairless mice. "
09/01/2012 - "Herein, we have investigated the effects of NO-exisulind on the growth of UVB-induced skin tumor development in a murine model. "
08/01/2012 - "Exisulind and its analogs have been shown to induce apoptosis in vitro in many cancer cell lines, including CaP cell lines without affecting normal human cells. "
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/01/2002 - "Exisulind is a novel oral anticancer agent that holds promise for the treatment of patients with advanced non-small cell lung cancer. "
09/01/2008 - "Exisulind is an apoptotic agent with preclinical activity in non-small cell lung cancer (NSCLC). "
09/01/2008 - "Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study."
03/01/2006 - "The study was designed to evaluate the safety and efficacy of exisulind, a selective apoptotic antineoplastic drug, in combination with gemcitabine as second-line therapy in patients with progressing advanced non-small cell lung cancer. "
03/01/2006 - "Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer."
03/01/2006 - "The decrease in median polyp size was significantly greater (p=0.03) in patients who received exisulind 400 mg (-10 mm2) compared with those who received placebo (-4 mm2). "
05/01/2000 - "Exisulind shows positive results in the prevention of precancerous colon polyps."
01/01/2004 - "In June 2000, Cell Pathways announced the results of a 1-year extension of a 1997-1999 phase III trial that showed that exisulind significantly reduced polyp formation in patients with FAP. "
11/01/2000 - "The patients continuing treatment with exisulind exhibited a further 50% reduction from their already reduced rate of polyp formation . "
11/01/2000 - "After 6 months of treatment with exisulind, 25 patients who had previously been taking placebo experienced a 50% reduction in polyp formation. "
|4.||Prostatic Neoplasms (Prostate Cancer)
01/01/2004 - "Exisulind has completed a pivotal phase II/III trial for preventing the recurrence of prostate cancer in the US. "
01/01/2004 - "In its 2003 Annual Report, Paladin Labs announced that it is conducting a phase III study of exisulind in patients with prostate cancer in Canada. "
09/01/2001 - "Our results support further study of Exisulind in the treatment of patients with prostate cancer."
12/01/2005 - "This drug profile reviews the evidence for the use of exisulind in the treatment of prostate cancer."
12/01/2005 - "Exisulind in the treatment of prostate cancer."
10/01/2007 - "In the absence of disease progression or intolerable side effects, patients continued taking 250 mg of exisulind orally, twice daily. "
03/01/2006 - "Complete or partial response was significantly higher in the exisulind 400 mg group (54.6%) compared with the placebo group (30.2%), and disease progression was significantly lower (6.1% v 27.9%) (p=0.04 and 0.02, respectively). "
09/01/2001 - "We evaluated the safety and efficacy of exisulind for delaying disease progression in men with increasing prostate specific antigen (PSA) after radical prostatectomy. "
|1.||sulindac sulfone (exisulind)
|3.||Cyclic GMP-Dependent Protein Kinases (Protein Kinase G)
|4.||Prostate-Specific Antigen (Semenogelase)
|2.||Prostatectomy (Retropubic Prostatectomy)
|3.||Heterologous Transplantation (Xenotransplantation)